Related Experiment Video

Updated: Aug 22, 2026

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases
09:36

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases

Published on: June 28, 2019

Ginkgo biloba and neurodegenerative disorders

Yves Christen1

  • 1IPSEN, 24 rue Erlanger, 75016 Paris, France. yves.christen@ipsen.com

Frontiers in Bioscience : a Journal and Virtual Library
|September 9, 2004
PubMed

Insights

Ginkgo biloba extract EGb 761 shows promise in preventing and treating neurodegenerative diseases like Alzheimer's. Ongoing studies will further clarify its effects and safety in humans.

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Ginkgo biloba extract EGb 761 is studied for neurodegenerative disease prevention and treatment.
  • Mechanisms include oxidative stress and beta-amyloid pathways in Alzheimer's disease.
  • Research has utilized animal models and human studies in healthy individuals, mild cognitive impairment, and Alzheimer's patients.

Purpose of the Study:

  • To review existing research on EGb 761 for neurodegenerative pathologies.
  • To identify knowledge gaps, particularly concerning pathogenesis.
  • To highlight ongoing interventional studies for Alzheimer's disease prevention.

Main Methods:

  • Review of existing literature on EGb 761.
  • Analysis of proposed mechanisms of action (oxidative stress, beta-amyloid).
  • Evaluation of data from animal models and human clinical trials.

Main Results:

  • EGb 761 demonstrates potential in managing neurodegenerative conditions.
  • Studies explore its role in mitigating oxidative stress and targeting beta-amyloid.
  • Existing data suggests a favorable safety profile.

Conclusions:

  • EGb 761 is a safe and potentially effective agent for neurodegenerative disorders.
  • Further interventional studies are crucial to confirm its efficacy in preventing Alzheimer's disease.
  • Continued research is needed to fully understand EGb 761's role in neuroprotection.

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...